Psoriasis Vulgaris
Conditions
Brief summary
To investigate the incretin effect and postprandial incretin responses in plasma in patients with psoriasis
Interventions
DIAGNOSTIC_TESTOral glucose tolerance test
Oral glucose tolerance test 50g
OTHERIntravenous isoglycaemic glucose clamp
Intravenous isoglycaemic glucose clamp
Liquid Mixed meal test 520 kcal
Sponsors
University Hospital, Gentofte, Copenhagen
Study design
Observational model
CASE_CONTROL
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Inclusion criteria
no diabetes BMI \< 27 kg/m\^2 normal Glucose tolerance test at screening normal fasting plasma glucose no islet auto antibodies no hormonel contraception informed consent psoriasis vulgaris (PASI\>8) (case not controls)
Exclusion criteria
other chronic inflammtory skin disease other chronic inflammatory disease pregnancy psychiatric illness
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incretin effect measured with Beta-cell secretory response | 0-180 minutes | Incretineffect (%) = 100 % × (Beta-cell Secretory Response (OGTT) - Beta-cell Secretory Response (IIGI)) / Beta-cell Secretory Response (OGTT) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Insulin sensitivity measures | 0-180 minutes | Matsudas insulin sensitivity index: (10,000 / √glucose minute 0 x insulin minute 0) (mean glucose (OGTT) x mean insulin OGTT)) |
| Concentration of Glucose-independent insulinotropic polypeptide | 0-180 minutes | Evaluted as Area Under the Curve |
| Concentration of Glucagon-like peptide 1 | 0-180 minuntes | Evaluated as Area Under the Curve |
| Concentration of Glucagon | 0-180 minutes | Evaluated as Area Under the Curve |
| Concentration of Insulin | 0-180 minutes | Evaluated as Area Under the Curve |
Outcome results
None listed